Biggest News Aggregation in the World
📰 Deric Dube News

Page 2 - Deric Dube News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Deric Dube. Real-time updates on events, politics, business and more.

Ligand's Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control

Ligand Pharmaceuticals Incorporated announced that its partner Travere Therapeutics, Inc. today released topline, two-year confirmatory secondary endpoint results from its pivotal, head-to-head...
Todd Davis Deric Dube Ligand Pharmaceuticals Incorporated Committee For Medicinal Products Human Use Gilead Sciences Ligand Pharmaceuticals

Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan

FILSPARI® achieved a clinically meaningful difference vs. irbesartan in eGFR total slope [p= 0.058] and eGFR chronic slope [p=0.037]. Patients treated with FILSPARI over two years exhibited one of...
United States Brad Rovin Nivi Nehra Deric Dube Naomi Eichenbaum Clinical Research Management

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q2 2023 Earnings Call Transcript

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q2 2023 Earnings Call Transcript August 4, 2023 Operator: Good day, and welcome to the Travere Therapeutics Second Quarter 2023 Financial Results and Corporate Update Conference Call. Today’s conference call is being recorded. At this time, I would like to turn the conference call over to the Vice President of Investor […]
Chris Cline Travere Totalcare Peter Heerma Deric Dube Naomi Eichenbaum Romaset Shutterstock
Source: yahoo.com

Travere Therapeutics Drug for Rare Kidney Disease Falls Short in Pivotal Test

Sparsentan failed to meet the main goal of a Phase 3 test in focal segmental glomerulosclerosis (FSGS). Nevertheless, Travere Therapeutics says the totality of data points to patient improvement in the rare kidney disorder and the biotech will talk with regulators about a potential path forward.
Jula Inrig Tim Lugo William Blair Deric Dube European Medicines Agency Travere Therapeutics

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science